carcinoma

(redirected from Nasopharyngeal carcinoma)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to Nasopharyngeal carcinoma: Burkitt's lymphoma

carcinoma:

see neoplasmneoplasm
or tumor,
tissue composed of cells that grow in an abnormal way. Normal tissue is growth-limited, i.e., cell reproduction is equal to cell death. Feedback controls limit cell division after a certain number of cells have developed, allowing for tissue repair
..... Click the link for more information.
.

carcinoma

[‚kärs·ən′ō·mə]
(medicine)
A malignant epithelial tumor.

carcinoma

Pathol
1. any malignant tumour derived from epithelial tissue
2. another name for cancer
References in periodicals archive ?
Diagnostic value of Epstein-Barr viral serology in nasopharyngeal carcinoma.
Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience.
Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.
Fine structure of nasopharyngeal carcinoma with reference to the anaplastic type.
Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy.
Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies.
EBV has also been implicated in other benign and malignant disorders such as infectious mononucleosis, Hodgkin's disease, non-Hodgkin lymphoma and nasopharyngeal carcinoma.
The association between specific serologic responses to Epstein-Barr virus (EBV) (5) and nasopharyngeal carcinoma (NPC) has been exploited to develop serologic tumor markers for this cancer (1).
We conducted a prospective study of 60 patients in a tertiary care referral center to ascertain the status of cell-mediated immunity as determined by delayed hypersensitivity reactions in patients with nasopharyngeal carcinoma (NPC) or allergic rhinitis.
Nimotuzumab was recently approved in China based on a 75% improvement in the complete response rate in patients diagnosed with squamous cell nasopharyngeal carcinoma (91% in patients treated with nimotuzumab plus radiotherapy versus 52% for those treated with radiotherapy alone).
A recent report (5) suggested that circulating Epstein-Barr virus DNA molecules from patients with nasopharyngeal carcinoma or lymphoma were relatively short, with 87% of them shorter than 181 bp.
Nimotuzumab was recently approved in China based on a 75% improvement in the complete response rate (91% vs 52%) in patients diagnosed with squamous cell nasopharyngeal carcinoma who were treated with nimotuzumab + radiotherapy versus radiotherapy alone.